Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27(8):1345–56.

Article  PubMed  CAS  Google Scholar 

Ibodeng GO, et al. A snapshot of lung cancer: where are we now?-a narrative review. Ann Transl Med. 2023;11(6):261.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cao M, et al. Cancer burden of major cancers in China: a need for sustainable actions. Cancer Commun (Lond). 2020;40(5):205–10.

Article  PubMed  Google Scholar 

Zhou Y et al. Implications of different cell death patterns for prognosis and immunity in lung adenocarcinoma. npj Precision Oncology, 2023;7 1:121.

Alexander M, Kim SY, Cheng H. Update 2020: management of non-small cell lung cancer. Lung. 2020;198(6):897–907.

Article  PubMed  PubMed Central  Google Scholar 

de Jong D. et al. Novel targets, novel treatments: the changing landscape of non-small cell lung cancer. Cancers (Basel). 2023;15 10.

Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. Jama. 2019;322(8):764–74.

Article  PubMed  CAS  Google Scholar 

Li MSC, Mok KKS, Mok TSK. Developments in targeted therapy & immunotherapy-how non-small cell lung cancer management will change in the next decade: a narrative review. Ann Transl Med. 2023;11(10):358.

Article  PubMed  PubMed Central  Google Scholar 

Müller S, et al. IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner. Nucleic Acids Res. 2019;47(1):375–90.

Article  PubMed  Google Scholar 

Basheer AS, et al. Role of inflammatory mediators, macrophages, and neutrophils in glioma maintenance and progression: mechanistic understanding and potential therapeutic applications. Cancers (Basel). 2021;13 16.

Zhong J, et al. Role of neutrophils on cancer cells and other immune cells in the tumor microenvironment. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 2023;1870 7:119493.

Di Ceglie I, et al. Immune cell networking in solid tumors: focus on macrophages and neutrophils. Front Immunol. 2024;15:1341390.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ouyang Y, et al. Tumor-associated neutrophils suppress CD8(+) T cell immunity in urothelial bladder carcinoma through the COX-2/PGE2/IDO1 Axis. Br J Cancer. 2024;130(5):880–91.

Article  PubMed  CAS  Google Scholar 

Zhang Q, et al. ETV4 mediated tumor-associated neutrophil infiltration facilitates lymphangiogenesis and lymphatic metastasis of bladder cancer. Adv Sci (Weinh). 2023;10(11):e2205613.

Article  PubMed  Google Scholar 

Li S, et al. Tumor-associated neutrophils induce EMT by IL-17a to promote migration and invasion in gastric cancer cells. J Exp Clin Cancer Res. 2019;38(1):6.

Article  PubMed  PubMed Central  Google Scholar 

Lee JH, Hong YM. The relationship between tumor-infiltrating neutrophils and clinical outcomes in patients with resectable hepatocellular carcinoma. BMC Cancer. 2024;24(1):327.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lin H, et al. Mutual regulation between N6-methyladenosine (m6A) modification and circular RNAs in cancer: impacts on therapeutic resistance. Mol Cancer. 2022;21(1):148.

Article  PubMed  PubMed Central  CAS  Google Scholar 

He L, et al. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18(1):176.

Article  PubMed  PubMed Central  Google Scholar 

Wang T, et al. The potential role of RNA N6-methyladenosine in cancer progression. Mol Cancer. 2020;19(1):88.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Han X, et al. Progression of m6A in the tumor microenvironment: hypoxia, immune and metabolic reprogramming. Cell Death Discovery. 2024;10(1):331.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhang Y, et al. Insights into N6-methyladenosine (m6A) modification of noncoding RNA in tumor microenvironment. Aging (Albany NY). 2023;15(9):3857–89.

Article  PubMed  CAS  Google Scholar 

Wang L, Tang Y. N6-methyladenosine (m6A) in cancer stem cell: From molecular mechanisms to therapeutic implications. Biomed Pharmacotherapy. 2023;163:114846.

Article  CAS  Google Scholar 

Yang S, et al. Link between m6A modification and infiltration characterization of tumor microenvironment in lung adenocarcinoma. Exp Biol Med (Maywood). 2023;248(23):2273–88.

Article  PubMed  CAS  Google Scholar 

Zeng Q-C, et al. Analysis of m6A modulator-mediated methylation modification patterns and the tumor microenvironment in lung adenocarcinoma. Scientific Reports. 2022;12(1):20684.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ye W, Huang T. Correlation analysis of m6A-modified regulators with immune microenvironment infiltrating cells in lung adenocarcinoma. PLoS One. 2022;17(2):e0264384.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Weng H, et al. The m(6)A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. Cancer Cell. 2022;40(12):1566-1582.e10.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Li T, et al. METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019;18(1):112.

Article  PubMed  PubMed Central  Google Scholar 

Duan M, et al. IGF2BPs as novel m6A readers: diverse roles in regulating cancer cell biological functions, hypoxia adaptation, metabolism, and immunosuppressive tumor microenvironment. Genes & Diseases. 2024;11(2):890–920.

Article  CAS  Google Scholar 

Wang Y, et al. Four m6A RNA methylation gene signatures and their prognostic values in lung adenocarcinoma. Technol Cancer Res Treat. 2022;21:15330338221085372.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yang J, et al. LCAT1 is an oncogenic LncRNA by stabilizing the IGF2BP2-CDC6 axis. Cell Death Dis. 2022;13(10):877.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Fang H, et al. m(6)A methylation reader IGF2BP2 activates endothelial cells to promote angiogenesis and metastasis of lung adenocarcinoma. Mol Cancer. 2023;22(1):99.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhang L, et al. P1.21-05 the upregulated expression of IGF2BP2 predicts poor prognosis in lung adenocarcinoma and affects immune microenvironment and drug sensitivity. Journal of Thoracic Oncology, 2023;18 11:S235-S236.

Murdocca M, et al. LOX-1 and cancer: an indissoluble liaison. Cancer Gene Therapy. 2021;28(10):1088–98.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tsumita T, et al. The oxidized-LDL/LOX-1 axis in tumor endothelial cells enhances metastasis by recruiting neutrophils and cancer cells. Int J Cancer. 2022;151(6):944–56.

Article  PubMed  CAS  Google Scholar 

Huang Y, et al. Intrapulmonary inoculation of multicellular spheroids to construct an orthotopic lung cancer xenograft model that mimics four clinical stages of non-small cell lung cancer. J Pharmacol Toxicol Methods. 2020;104:106885.

Article  PubMed  CAS